{"id":"NCT00742391","sponsor":"Peplin","briefTitle":"A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations","officialTitle":"A Multi-center, Randomized, Parallel Group, Double-blind, Vehicle-controlled Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, 0.05% In Patients With Actinic Keratoses ON Non-head Locations (REGION-I)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-09","primaryCompletion":"2009-02","completion":"2009-02","firstPosted":"2008-08-27","resultsPosted":"2012-03-21","lastUpdate":"2015-03-06"},"enrollment":255,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Actinic Keratoses"],"interventions":[{"type":"DRUG","name":"PEP005 (ingenol mebutate) Gel","otherNames":[]},{"type":"DRUG","name":"Vehicle gel","otherNames":[]}],"arms":[{"label":"1","type":"ACTIVE_COMPARATOR"},{"label":"2","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to determine whether topical application of PEP005 is effective for the treatment of actinic keratoses.","primaryOutcome":{"measure":"Patients With Complete Clearance of Actinic Keratosis (AKs)","timeFrame":"57 days","effectByArm":[{"arm":"PEP005 (Ingenol Mebutate) Gel","deltaMin":35,"sd":null},{"arm":"Vehicle Gel","deltaMin":6,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":3},"locations":{"siteCount":20,"countries":["United States","Australia"]},"refs":{"pmids":["22417254"],"seeAlso":["http://www.fda.gov/","http://www.tga.gov.au/"]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":125},"commonTop":[]}}